Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce Sells 17,500 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $46.94, for a total value of $821,450.00. Following the sale, the chief executive officer now directly owns 85,942 shares of the company’s stock, valued at approximately $4,034,117.48. This trade represents a 16.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, October 23rd, Marshall Fordyce sold 19,375 shares of Vera Therapeutics stock. The stock was sold at an average price of $40.39, for a total value of $782,556.25.
• On Wednesday, October 9th, Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock. The shares were sold at an average price of $38.24, for a total value of $597,500.00.
• On Wednesday, September 25th, Marshall Fordyce sold 23,125 shares of Vera Therapeutics stock. The shares were sold at an average price of $46.05, for a total value of $1,064,906.25.

Vera Therapeutics Stock Performance

Shares of VERA traded down $1.06 during mid-day trading on Friday, reaching $44.05. The company had a trading volume of 540,987 shares, compared to its average volume of 875,890. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The firm has a 50-day moving average price of $44.94 and a 200 day moving average price of $40.27. Vera Therapeutics, Inc. has a 52 week low of $14.08 and a 52 week high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). Equities research analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on VERA shares. JPMorgan Chase & Co. boosted their price target on Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Cantor Fitzgerald restated an “overweight” rating and set a $107.00 price target on shares of Vera Therapeutics in a report on Tuesday, October 1st. Wells Fargo & Company started coverage on Vera Therapeutics in a report on Thursday, November 21st. They set an “overweight” rating and a $70.00 price target on the stock. Guggenheim boosted their price target on Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Monday, October 28th. Finally, Scotiabank started coverage on Vera Therapeutics in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 price target on the stock. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Vera Therapeutics has an average rating of “Buy” and an average price target of $59.22.

Institutional Trading of Vera Therapeutics

A number of hedge funds have recently made changes to their positions in VERA. Cetera Advisors LLC bought a new stake in shares of Vera Therapeutics in the 1st quarter worth approximately $235,000. William Marsh Rice University bought a new position in Vera Therapeutics in the 2nd quarter valued at approximately $593,000. EFG Asset Management North America Corp. lifted its position in Vera Therapeutics by 204.0% in the 2nd quarter. EFG Asset Management North America Corp. now owns 31,444 shares of the company’s stock valued at $1,137,000 after acquiring an additional 21,101 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Vera Therapeutics by 6.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 165,322 shares of the company’s stock valued at $5,981,000 after acquiring an additional 9,854 shares in the last quarter. Finally, Legato Capital Management LLC bought a new position in Vera Therapeutics in the 2nd quarter valued at approximately $273,000. 99.21% of the stock is owned by institutional investors.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.